A new age of genetic screening is coming — and we don’t have any rules for it
By Dalton Conley,
The Washington Post
| 06. 14. 2021
New ‘polygenic’ screening techniques open a Pandora’s Box of ethical issues.
After the coronavirus baby bust is over and fertility clinics are booming again, increasing numbers of new parents will bring home a generation of infants prescreened to perform better at school or basketball, resist heart disease or be less likely to have schizophrenia.
It may not be common yet, but the ability to screen embryos for any number of traits is here now, and improving every day. And this brave new world of genetic prediction I’m describing is not just about selecting babies during in vitro fertilization. It could also involve life insurance companies swabbing your cheek before issuing you a policy, preschools and colleges scoring your DNA as part of their admissions process and dating sites asking for your genetic profile before offering you a match.
But with this new technology comes countless ethical questions. Is embryo selection a good thing or a bad thing — or both? How do we balance potential inequities created against potential lives saved or improved? Do we want to keep genetics from becoming destiny, and what does that even mean? We desperately need...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
By Judd Boaz and Elise Kinsella, ABC News | 03.17.2026
By Ryan Cross, Endpoints News | 03.24.2026
Cathy Tie has an audacity more typical of a tech startup founder than a biotech executive. She dropped out of college to start a genetic screening company and later founded a telemedicine startup. The 29-year-old has been on two Forbes...